Biofrontera

Biofrontera Equity Growth

The Year-over-Year Equity Growth of Biofrontera (B8FK.DE) as of Nov 21, 2026 is -20.95 %. In the previous year, Year-over-Year Equity Growth was -5.63 % — a change of 272.47% (lower).

Equity Growth

-20.95 %

YoY

272.47%

Last updated:

Year-over-Year Equity Growth of Biofrontera is 2025 -20.95 % . Year-over-Year Equity Growth of Biofrontera was 2024 -5.63 % . It decreases by 272.47% lower compared to the previous year.

The Biofrontera Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
383.76 EUR
Jan 1, 2019
-39.14 EUR
Jan 1, 2020
-25.92 EUR
Jan 1, 2021
678.66 EUR
Jan 1, 2022
-64.59 EUR
Jan 1, 2023
-1.75 EUR
Jan 1, 2024
-5.63 EUR
Jan 1, 2025
-20.95 EUR
The Biofrontera Equity Growth history
YEAREquity GrowthYoY
-20.95 %+272.47%
-5.63 %+221.36%
-1.75 %-97.29%
-64.59 %-109.52%
678.66 %-2,718.62%
-25.92 %-33.78%
-39.14 %-110.20%
383.76 %-587.89%
-78.66 %-118.32%
429.42 %-101.88%
-22,801.86 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Year-over-Year Equity Growth of Biofrontera is -20.95 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Biofrontera since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Biofrontera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Biofrontera

All Key Metrics — Biofrontera